Six things to know:
1. The service line was sold to Vilex, an affiliate of Squadron Capital, in a Dec. 31 transaction.
2. Vilex now has a restricted license to manufacture and sell products utilizing the external fixation technology developed by OrthoPediatrics affiliate Orthex. OrthoPediatrics has the right to use and sell certain intellectual property that was acquired.
3. OrthoPediatrics first announced plans to divest the Vilex Adult Business when it acquired Vilex in Tennessee and Orthex in June 2019. Squadron helped finance those deals.
4. The divestiture reduced the amount OrthoPediatrics owed to Squadron Capital under a Term Note B by $25 million. OrthoPediatrics repaid the remaining $5 million of principal outstanding, plus all accrued interest, with funds from its revolving credit facility with Squadron Capital.
5. OrthoPediatrics President and CEO Mark Throdahl said the divestiture demonstrates his company’s ability to strategically position itself for sustainable future growth and maintain a leading position in pediatric orthopedics.
6. OrthoPediatrics markets 33 surgical systems for specialties including trauma and deformity, scoliosis, and sports medicine. It distributes products in the U.S. and 43 other countries.
More articles on practice management:
Orthopedic clinic faces renewed lawsuit over 2016 cyberattack
Orthopedics unit restructures workforce to boost efficiency — 5 details
Optim Orthopedics performs four free joint replacements
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
